Login with your work email address to view charts. No credit card required.
| Art Unit: | 1622 — Drug, bio-affecting and body treating compositions |
|---|---|
| Group: | 1620 — Biomedicinal Chemistry |
| Classes: |
514 — Drug, bio-affecting and body treating compositions 548 — Organic compounds -- part of the class 532-570 series 424 — Drug, bio-affecting and body treating compositions 549 — Organic compounds -- part of the class 532-570 series 544 — Organic compounds -- part of the class 532-570 series 556 — Organic compounds -- part of the class 532-570 series 552 — Organic compounds -- part of the class 532-570 series |
| Phone: | (571) 270-0589 |
| Email: | None |
| Location: | None |
| Title: | Pat Examnr Gen Chem |
| Service: | 3 years |
| Grade: | GS-11 |
| 3-Year Grant rate: | 9% over 11 cases |
|---|---|
| Difficulty: | Extremely Hard |
| Difficulty Percentile: | 96th
|
With Examiner Eleniste, you have a 9% chance of getting an issued patent by 3 years after the first office action. Examiner Eleniste is an extremely hard examiner and in the 96th percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Eleniste, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Eleniste's grant rate is lower than that of Art Unit 1622 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Eleniste | 2.1 |
| Art Unit 1622 | 1.1 |
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.